Drug intelligence / Profile preview

ORP-110

Development stage: Unknown
Lead developer: OrphoMed
Modality: Small Molecules

Overview

ORP-110 is an investigational small molecule developed by OrphoMed, Inc. as a **CFTR (cystic fibrosis transmembrane conductance regulator) stimulant** for the treatment of **cystic fibrosis**. It is designed to enhance CFTR function, potentially addressing the underlying defect in chloride ion transport characteristic of the disease. Currently in the **discovery stage**, with preclinical development focused on this rare genetic disorder affecting the lungs and other organs.[7][19]

Targets

CFTR (Cystic fibrosis transmembrane conductance regulator)

Beyond the preview

Go deeper on ORP-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORP-110.

Explore the full profile